Victory Capital Management Inc. Acquires New Stake in BioNTech SE (NASDAQ:BNTX)

Victory Capital Management Inc. acquired a new stake in BioNTech SE (NASDAQ:BNTX) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 2,907 shares of the company’s stock, valued at approximately $345,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Baillie Gifford & Co. lifted its position in BioNTech by 0.4% in the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after acquiring an additional 31,773 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its position in BioNTech by 4.3% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after buying an additional 24,426 shares in the last quarter. Candriam S.C.A. lifted its position in BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after buying an additional 418,695 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its position in BioNTech by 12.6% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company’s stock worth $56,886,000 after buying an additional 53,800 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its position in BioNTech by 283.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after buying an additional 341,311 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on BNTX. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. HSBC boosted their price target on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. TD Cowen cut their price target on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research report on Tuesday, November 5th. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. Finally, Canaccord Genuity Group boosted their price objective on shares of BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research note on Wednesday. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $138.67.

BioNTech Stock Down 1.9 %

Shares of BNTX opened at $118.39 on Friday. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The firm has a market cap of $28.38 billion, a P/E ratio of -56.94 and a beta of 0.26. The firm’s 50-day simple moving average is $113.69 and its 200 day simple moving average is $98.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same quarter in the prior year, the business earned $0.73 EPS. BioNTech’s quarterly revenue was up 38.9% on a year-over-year basis. On average, analysts forecast that BioNTech SE will post -3.68 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.